MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...

Feature photo: The diagram represents a key work process facilitated by BuisnessOutside at the NAW Innovation retreat. See a full-size version at the end of this article. Mark Dancer: NAW Fellow, ...

Distributors have a long history of agility. It’s an essential capability for a business model that operates on razor-thin margins even in the best of times. As the only constant in the market in ...